STOCK TITAN
  1. Home
  2. Sec-filings
  3. INCY
  4. [144] Incyte Genomics Inc SEC Filing

[144] Incyte Genomics Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock INCY logo
Incyte Corp

NASDAQ:INCY

INCY Rankings

#661 Ranked by Market Cap
N/A Ranked by Dividends

INCY Latest News

Oct 8, 2025
Incyte to Report Third Quarter Financial Results
Sep 24, 2025
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 22, 2025
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
Sep 18, 2025
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
Sep 17, 2025
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

INCY Latest SEC Filings

Oct 6, 2025
[Form 4] INCYTE CORP Insider Trading Activity
Oct 3, 2025
[144] INCYTE CORP SEC Filing
Oct 3, 2025
[Form 4] INCYTE CORP Insider Trading Activity
Oct 3, 2025
[Form 4] INCYTE CORP Insider Trading Activity
Oct 3, 2025
[8-K] INCYTE CORP Reports Material Event

INCY Stock Data

17.03B
190.92M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON